Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.440
-0.040 (-2.70%)
At close: Jul 26, 2024, 4:00 PM
1.450
+0.010 (0.69%)
After-hours: Jul 26, 2024, 6:40 PM EDT
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $32.61M in the quarter ending March 31, 2024, a decrease of -18.49%. This brings the company's revenue in the last twelve months to $187.23M, down -30.88% year-over-year. In the year 2023, Akebia Therapeutics had annual revenue of $194.62M, down -33.46%.
Revenue (ttm)
$187.23M
Revenue Growth
-30.88%
P/S Ratio
1.64
Revenue / Employee
$1,121,108
Employees
167
Market Cap
301.82M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MultiPlan | 959.44M |
Accolade | 431.53M |
AngioDynamics | 324.01M |
Viemed Healthcare | 194.05M |
Alimera Sciences | 90.22M |
SOPHiA GENETICS | 64.18M |
Aquestive Therapeutics | 51.50M |
Nyxoah | 5.57M |
AKBA News
- 15 days ago - Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets - PRNewsWire
- 25 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - PRNewsWire
- 4 weeks ago - Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference - PRNewsWire
- 2 months ago - Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 3 months ago - Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights - PRNewsWire